259 related articles for article (PubMed ID: 35411416)
1. Albumin-Embellished Arsenic Trioxide-Loaded Polymeric Nanoparticles Enhance Tumor Accumulation and Anticancer Efficacy via Transcytosis for Hepatocellular Carcinoma Therapy.
Huang Y; Xu Z; Wei Y; Han S; Cai X; Chen D
AAPS PharmSciTech; 2022 Apr; 23(4):111. PubMed ID: 35411416
[TBL] [Abstract][Full Text] [Related]
2. Nanocarrier-based delivery of arsenic trioxide for hepatocellular carcinoma therapy.
Sun J; Cheng M; Ye T; Li B; Wei Y; Zheng H; Zheng H; Zhou M; Piao JG; Li F
Nanomedicine (Lond); 2022 Nov; 17(26):2037-2054. PubMed ID: 36789952
[TBL] [Abstract][Full Text] [Related]
3. Delivery of Arsenic Trioxide by Multifunction Nanoparticles To Improve the Treatment of Hepatocellular Carcinoma.
Wu Q; Chen X; Wang P; Wu Q; Qi X; Han X; Chen L; Meng X; Xu K
ACS Appl Mater Interfaces; 2020 Feb; 12(7):8016-8029. PubMed ID: 31997633
[TBL] [Abstract][Full Text] [Related]
4. pH-Responsive and liver-targeting drug delivery system for combination delivery of artesunate with arsenic trioxide prodrug against hepatocellular carcinoma.
Pan X; Huang J; Liu S; Shao Y; Xi J; He R; Shi T; Zhuang R; Yu W
Drug Dev Ind Pharm; 2023 Aug; 49(8):485-496. PubMed ID: 37470495
[TBL] [Abstract][Full Text] [Related]
5. Arsenic-Loaded Biomimetic Iron Oxide Nanoparticles for Enhanced Ferroptosis-Inducing Therapy of Hepatocellular Carcinoma.
Liu J; Li X; Chen J; Zhang X; Guo J; Gu J; Mei C; Xiao Y; Peng C; Liu J; Hu X; Zhang K; Li D; Zhou B
ACS Appl Mater Interfaces; 2023 Feb; 15(5):6260-6273. PubMed ID: 36695492
[TBL] [Abstract][Full Text] [Related]
6. ZnAs@SiO
Huang Y; Zhou B; Luo H; Mao J; Huang Y; Zhang K; Mei C; Yan Y; Jin H; Gao J; Su Z; Pang P; Li D; Shan H
Theranostics; 2019; 9(15):4391-4408. PubMed ID: 31285768
[No Abstract] [Full Text] [Related]
7. MMP2-responsive dual-targeting drug delivery system for valence-controlled arsenic trioxide prodrug delivery against hepatic carcinoma.
Li C; Zhang K; Liu A; Yue T; Wei Y; Zheng H; Piao JG; Li F
Int J Pharm; 2021 Nov; 609():121209. PubMed ID: 34678398
[TBL] [Abstract][Full Text] [Related]
8. PEG-grafted arsenic trioxide-loaded mesoporous silica nanoparticles endowed with pH-triggered delivery for liver cancer therapy.
Jiang L; Wang X; Raza F; Zhong H; Su J; Yuan WE; Qiu M
Biomater Sci; 2023 Jul; 11(15):5301-5319. PubMed ID: 37357799
[TBL] [Abstract][Full Text] [Related]
9. Chemoembolizing hepatocellular carcinoma with microsphere cored with arsenic trioxide microcrystal.
Kong D; Jiang T; Liu J; Jiang X; Liu B; Lou C; Zhao B; Carroll SL; Feng G
Drug Deliv; 2020 Nov; 27(1):1729-1740. PubMed ID: 33307843
[TBL] [Abstract][Full Text] [Related]
10. Arsenic trioxide-induced upregulation of miR-1294 suppresses tumor growth in hepatocellular carcinoma by targeting TEAD1 and PIM1.
Cai X; Yu L; Chen Z; Ye F; Ren Z; Jin P
Cancer Biomark; 2020; 28(2):221-230. PubMed ID: 32280078
[TBL] [Abstract][Full Text] [Related]
11. Shikonin potentiates the effect of arsenic trioxide against human hepatocellular carcinoma in vitro and in vivo.
Song J; Zhao Z; Fan X; Chen M; Cheng X; Zhang D; Wu F; Ying X; Ji J
Oncotarget; 2016 Oct; 7(43):70504-70515. PubMed ID: 27655700
[TBL] [Abstract][Full Text] [Related]
12. Combination of canstatin and arsenic trioxide suppresses the development of hepatocellular carcinoma.
Zhang F; Duan J; Song H; Yang L; Zhou M; Wang X
Drug Dev Res; 2021 May; 82(3):430-439. PubMed ID: 33244794
[TBL] [Abstract][Full Text] [Related]
13. Targeted arsenite-loaded magnetic multifunctional nanoparticles for treatment of hepatocellular carcinoma.
Chi X; Zhang R; Zhao T; Gong X; Wei R; Yin Z; Lin H; Li D; Shan H; Gao J
Nanotechnology; 2019 Apr; 30(17):175101. PubMed ID: 30654348
[TBL] [Abstract][Full Text] [Related]
14. Arsenic trioxide inhibits liver cancer stem cells and metastasis by targeting SRF/MCM7 complex.
Wang HY; Zhang B; Zhou JN; Wang DX; Xu YC; Zeng Q; Jia YL; Xi JF; Nan X; He LJ; Yue W; Pei XT
Cell Death Dis; 2019 Jun; 10(6):453. PubMed ID: 31186405
[TBL] [Abstract][Full Text] [Related]
15. Arsenic trioxide augments immunogenic cell death and induces cGAS-STING-IFN pathway activation in hepatocellular carcinoma.
Li X; Pan YF; Chen YB; Wan QQ; Lin YK; Shang TY; Xu MY; Jiang TY; Pei MM; Tan YX; Dong LW; Wan XY
Cell Death Dis; 2024 Apr; 15(4):300. PubMed ID: 38684648
[TBL] [Abstract][Full Text] [Related]
16. Lipid/PAA-coated mesoporous silica nanoparticles for dual-pH-responsive codelivery of arsenic trioxide/paclitaxel against breast cancer cells.
Zhang BB; Chen XJ; Fan XD; Zhu JJ; Wei YH; Zheng HS; Zheng HY; Wang BH; Piao JG; Li FZ
Acta Pharmacol Sin; 2021 May; 42(5):832-842. PubMed ID: 33824461
[TBL] [Abstract][Full Text] [Related]
17. Liposome-Coated Arsenic-Manganese Complex for Magnetic Resonance Imaging-Guided Synergistic Therapy Against Carcinoma.
Jin Z; Yi X; Yang J; Zhou M; Wu P; Yan G
Int J Nanomedicine; 2021; 16():3775-3788. PubMed ID: 34113100
[TBL] [Abstract][Full Text] [Related]
18. pH-triggered sustained release of arsenic trioxide by polyacrylic acid capped mesoporous silica nanoparticles for solid tumor treatment in vitro and in vivo.
Xiao X; Liu Y; Guo M; Fei W; Zheng H; Zhang R; Zhang Y; Wei Y; Zheng G; Li F
J Biomater Appl; 2016 Jul; 31(1):23-35. PubMed ID: 27059495
[TBL] [Abstract][Full Text] [Related]
19. Arsenic trioxide induces differentiation of cancer stem cells in hepatocellular carcinoma through inhibition of LIF/JAK1/STAT3 and NF-kB signaling pathways synergistically.
Zhang X; Hu B; Sun YF; Huang XW; Cheng JW; Huang A; Zeng HY; Qiu SJ; Cao Y; Fan J; Zhou J; Yang XR
Clin Transl Med; 2021 Feb; 11(2):e335. PubMed ID: 33634982
[TBL] [Abstract][Full Text] [Related]
20. Arsenic trioxide reverses the chemoresistance in hepatocellular carcinoma: a targeted intervention of 14-3-3η/NF-κB feedback loop.
Qiu Y; Dai Y; Zhang C; Yang Y; Jin M; Shan W; Shen J; Lu M; Tang Z; Ju L; Wang Y; Jiao R; Xia Y; Huang G; Yang L; Li Y; Zhang J; Wong VKW; Jiang Z
J Exp Clin Cancer Res; 2018 Dec; 37(1):321. PubMed ID: 30572915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
